Abstract:Sathyaprasad Burjonrappa Department of Pediatric Surgery, Rutgers, State University of New Jersey, New Brunswick, NJ, USA Comment on: Weil BR, Murphy AJ, Liu Q, et al . Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2023;41:2638-50. Keywords: Wilms tumor (WT); chronic health conditions; late health outcomes; second malignant neoplasm Submitted Dec 03, 2023. Accepted for publication Jan 16, 2024. Published online Feb 27, 2024. doi: 10.21037/tp-23-579 It is a pleasure to write the editorial commentary on a landmark paper by Weil and colleagues recently published in the Journal of Clinical Oncology (1). The improvement in Wilms tumor (WT) survival, with 85–90% 5-year survivals, can be attributed to risk adjusted standardization of therapy based on protocols developed by the Children's Oncology Group (COG) in the United States (USA) and SIOP (Societie International Oncology Pediatrique) in Europe over the last half century. The focus has now rightly shifted to understanding long-term health consequences in WT survivors of current treatment protocols. The paper was very well designed to study the long-term health related disease burden and suggest potential changes to treatment paradigms by understanding the consequences of risk adjusted multimodal therapy. It evaluated the incidence of long-term morbidity after treatment for unilateral nonsyndromic WT in a cohort of 2,008 survivors by studying the 35-year cumulative incidence of death and development of any grade 3–5 chronic health condition (CHC) to a matched cohort (2:1) of siblings of cancer survivors. WT patients in the cohort were treated between 1970 and 1999. The use of the Childhood Cancer Survivor Study (CCSS) and linking it to the National Death Index helped establish late mortality (beyond 5 years of therapy) and cause of death in the study. The authors proceed to further classify late deaths as due to WT relapse, other health related causes (including late effects of therapy), or external causes. Subsequent Malignant Neoplasm (SMN) incidence was ascertained by self-reporting and medical record review. CHCs were graded according to Common Technology Criteria for Adverse Events (CTCAE) as mild (Grade 1); moderate (Grade 2); disabling (Grade 3); life threatening (Grade 4); and fatal (Grade 5). In selecting grade 3–5 CHCs for further study the authors have rightly focused on the most commonly known causes of morbidity after WT surgery including intestinal obstruction needing operative intervention, kidney failure requiring dialysis or transplant, heart failure, and Premature Ovarian Insufficiency (POI) before age 40 years in females. Standardized Short Form-36 answers dichotomized to impaired/non impaired was used to subjectively measure health related quality of life (HRQOL). Covariates included demographic data and treatment exposure. Chemotherapy (CT) exposure was evaluated based on established WT regimens while radiotherapy (RT) exposure was subdivided to (I) ipsilateral flank RT; (II) whole abdominal RT (WART); and (III) whole lung RT (WLRT). Further exposure was evaluated by RT site and RT dose. Survivors were stratified for two field categories [WLRT and abdominal radiotherapy (ART)] and dose was categorized as ≥20 or ≤20 Gy. The authors have included all variables that affect risk for CHCs after WT treatment and develop treatment attributable risk based on exposure. Median age of survivor cohort at diagnosis and follow-up were 3.2 years (range, 0–20.2 years) and 27.8 years (range, 6.4–57.5 years). The true merit of this study lies in the length of follow-up that has been obtained. All survivors in cohort had undergone nephrectomy and nearly all (98.1%) received CT with vincristine (93.8%) and actinomycin D (93.5%) while doxorubicin was used in 44.8%. Use of other agents (etoposide, cyclophosphamide, and platinum agents) was more common after the 1990's as compared to those treated in the 70's and 80's. As would be expected, with greater disease burden, treatment group with >4 medications had the greatest proportion of survivors experiencing early relapse (23.2%). Doxorubicin use was also more common over time but cumulative dose exposure (≥250 mg/m 2 ) decreased over time. Fifty-five percent of survivors received RT with most common fields being flank (27.8%); WART (13.8%) and WLRT (13.4%). There were 142 late deaths (7.8%). Most importantly health related mortality (4.7%) was nearly three times relapse-related mortality (1.6%). This I believe is going to be important in making treatment decisions in the future. Most frequent causes of death were SMN (n=42), WT relapse (n=30), and cardiac. (n=9). Breast cancer was the most commonly reported SMN [standardized incidence ratio (SIR) of 4.1] and was highest in the group that received VAD (vincristi -Abstract Truncated-

Survivorship issues beyond 2 years after treatment in testicular germ cell tumors: Experience from a large centre in the United Kingdom.

Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment

Long-term Relapse and Survival in Clinical Stage I Testicular Teratoma

GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee

Long-term effects on sexual function and fertility after treatment of testicular cancer

First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

Sexual and Reproductive Healthcare Following Gonadotoxic Treatment in Females at a Tertiary Pediatric Hospital

Patient-reported survivorship care practices and late effects after treatment of Hodgkin (HL) and non-Hodgkin lymphoma (NHL).

Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience

Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study)

Abstract 1306: Preferences for survivorship care among AYA cancer survivors and challenges of cancer specialist-led follow up

Late health outcome among survivors of Wilms tumor

Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review

Australia and New Zealand (ANZ) outcomes of high-dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumors (GCT) from 1999 to 2019: Multicenter registry-based study with ABMTRR.

A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial

Follow-up after primary therapy for endometrial cancer: A systematic review

Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects

From Storage to Survivorship: A Scoping Review of Young Adult Cancer Survivors' Experiences and Preferences in Reproductive Survivorship Care after Fertility Tissue Preservation

A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors

Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors